Physician profile
Jeffrey Morris
NPI 1144720640
$2,994.47
in general payments reported to CMS, 2019-2025
21 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $237 · 2021: $651 · 2022: $954 · 2023: $500 · 2024: $489 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $479.41 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $303.96 | 2021-2022 | |
| Abbvie INC. | $254.98 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $222.79 | 2022-2025 | |
| Genzyme Corporation | $173.19 | 2022-2024 | |
| Pfizer INC. | $133.54 | 2022 | |
| Incyte Corporation | $126.03 | 2022 | |
| Amgen INC. | $122.97 | 2021-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $110.61 | 2023-2025 | |
| Leo Pharma INC. | $81.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.53 | 2022-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $69.99 | 2022 | |
| Janssen Biotech, INC. | $45.89 | 2022-2023 | Remicade, Simponi, Simponi Aria |
| Lilly USA, LLC | $45.43 | 2022-2024 | Taltz |
| Helsinn Therapeutics (U.S.), INC. | $29.06 | 2023-2025 | Valchlor |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $25.72 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Organon LLC | $23.37 | 2025 | |
| Dermavant Sciences, INC. | $22.88 | 2024 | Vtama |
| Biofrontera INC. | $20.88 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Ucb, INC. | $15.74 | 2022 | |
| Angiodynamics, INC. | $13.19 | 2024 | Venacure 1470 Pro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.